Almanya\u2019n\u0131n Heidelberg kentindeki Alman Kanser Ara\u015ft\u0131rma Merkezi taraf\u0131ndan yap\u0131lan \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir \u00e7al\u0131\u015fma, kolorektal kanser (KRK) tarama testlerinde y\u00fcksek hassasiyetin her zaman maliyet etkinli\u011fi art\u0131rmad\u0131\u011f\u0131n\u0131 ortaya koydu. Annals of Internal Medicine dergisinin yakla\u015fan say\u0131s\u0131nda yay\u0131mlanacak ara\u015ft\u0131rmada, geleneksel d\u0131\u015fk\u0131da insan imm\u00fcnokimyasal testi (FIT) ile multitarget d\u0131\u015fk\u0131 DNA testleri (MSDT) ve yeni nesil multitarget d\u0131\u015fk\u0131 DNA testleri (N-G MSDT) ekonomik a\u00e7\u0131dan k\u0131yasland\u0131. \u00c7al\u0131\u015fma, erken tespit edilen KRK ve ileri neoplazi vakalar\u0131na ula\u015f\u0131rken maliyet etkinli\u011finin kritik bir unsur oldu\u011funu vurguluyor ve FIT\u2019in, daha y\u00fcksek maliyetle gelen MSDT y\u00f6ntemlerine g\u00f6re hala \u00f6ne \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n
Kolorektal kanser, d\u00fcnya genelinde kanser kaynakl\u0131 \u00f6l\u00fcmlerde \u00fcst s\u0131ralarda yer almakta ve hastal\u0131\u011f\u0131n erken te\u015fhisi i\u00e7in tarama programlar\u0131 b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r. MSDT ve N-G MSDT, \u00f6zellikle ileri neoplazi ve erken evre KRK tespiti konusunda klasik FIT testinden daha y\u00fcksek hassasiyet vaat ederken, bu avantaj\u0131n y\u00fcksek test maliyetleri ve sa\u011fl\u0131k sistemlerine getirdi\u011fi ekonomik y\u00fckle dengelenmesi gerekiyor. \u00c7al\u0131\u015fmada Medicare geri \u00f6deme oranlar\u0131, test maliyetleri ve hastalar\u0131n takip kolonoskopisine uyumu dikkate al\u0131narak kapsaml\u0131 bir ekonomi analizi yap\u0131ld\u0131.<\/p>\n
Ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131na g\u00f6re, MSDT tabanl\u0131 y\u00f6ntemlerle erken tespit edilen her bir KRK veya ileri neoplazi vakas\u0131 i\u00e7in yap\u0131lan tarama maliyetleri, FIT ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda 7 ila 9 kat daha fazla. \u0130lgin\u00e7 bir bi\u00e7imde, MSDT ve N-G MSDT fiyatlar\u0131 mevcut d\u00fczeylerinin %20\u2019sine kadar d\u00fc\u015f\u00fcr\u00fclse bile, bu testlerin FIT\u2019e k\u0131yasla maliyet etkinli\u011fini sa\u011flamak m\u00fcmk\u00fcn olmuyor. Bu veriler, toplumsal sa\u011fl\u0131k politikalar\u0131nda test hassasiyeti ile ekonomik s\u00fcrd\u00fcr\u00fclebilirlik aras\u0131nda dengeli kararlar al\u0131nmas\u0131 gerekti\u011fini g\u00fc\u00e7l\u00fc bir bi\u00e7imde ortaya koyuyor.<\/p>\n
\u00c7al\u0131\u015fmada, pozitif d\u0131\u015fk\u0131 testinin ard\u0131ndan uygulanacak takip kolonoskopisine y\u00f6nelik hasta uyumu farkl\u0131 senaryolarla modellenmi\u015ftir. Takip oranlar\u0131 %30\u2019dan %90\u2019a kadar de\u011fi\u015ftirildi\u011finde, d\u00fc\u015f\u00fck kolonoskopi uyumu durumunda MSDT\u2019nin ek maliyetleri FIT\u2019e k\u0131yasla 1,4 milyon dolar\u0131n, N-G MSDT\u2019nin ise 1,5 milyon dolar\u0131n \u00fczerine \u00e7\u0131k\u0131yor. En y\u00fcksek uyum oranlar\u0131nda bile her erken tespit edilen vaka i\u00e7in ek maliyetler yar\u0131m milyon dolar\u0131n \u00fcst\u00fcnde kal\u0131yor. Bu da MSDT y\u00f6ntemlerinin ekonomik a\u00e7\u0131dan halen \u00f6nemli sorunlar ta\u015f\u0131d\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n
Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca, MSDT\u2019nin y\u00fcksek hassasiyetinin, FIT\u2019nin pozitiflik e\u015fiklerinin ayarlanmas\u0131 suretiyle yak\u0131n d\u00fczeyde sa\u011flanabilece\u011fini ifade ediyor. Bu \u00f6neri, daha pahal\u0131 molek\u00fcler testlere k\u0131yasla, maliyetleri artt\u0131rmaks\u0131z\u0131n etkili tan\u0131sal performansa sahip FIT testlerinin \u00f6nemini vurguluyor ve tarama protokollerinin bu do\u011frultuda yeniden kalibre edilmesi gereklili\u011fine i\u015faret ediyor. B\u00f6ylece klinik etkinlik ve ekonomik verimlilik dengede tutulabilir.<\/p>\n
Metodolojik a\u00e7\u0131dan, \u00e7al\u0131\u015fma, Cologuard ve Cologuard Plus olarak bilinen MSDT ve N-G MSDT testlerinin tan\u0131sal do\u011frulu\u011funu ticari FIT testleriyle kar\u015f\u0131la\u015ft\u0131ran iki ba\u011f\u0131ms\u0131z kohorttan toplanan verilerle y\u00fcr\u00fct\u00fcld\u00fc. Medicare geri \u00f6deme oranlar\u0131 ve kolonoskopi uyum oranlar\u0131, erken evre KRK ve ileri neoplazi te\u015fhisi ba\u015f\u0131na tarama maliyetlerinin hesaplanmas\u0131nda entegre edildi. Bu y\u00f6ntem, ger\u00e7ek\u00e7i ve uygulanabilir bir maliyet etkinli\u011fi modelinin geli\u015fimine katk\u0131 sa\u011flamaktad\u0131r.<\/p>\n
Bu bilgilerin \u0131\u015f\u0131\u011f\u0131nda, \u00e7al\u0131\u015fma, multitarget d\u0131\u015fk\u0131 DNA testlerinin toplum tabanl\u0131 KRK tarama programlar\u0131nda mutlak bir \u00fcst\u00fcnl\u00fckle benimsenmesi gerekti\u011fi g\u00f6r\u00fc\u015f\u00fcn\u00fc sorguluyor. Sa\u011fl\u0131k b\u00fct\u00e7elerinin s\u0131n\u0131rland\u0131r\u0131lm\u0131\u015f olmas\u0131 ve kaynaklar\u0131n etkin kullan\u0131m ihtiyac\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, FIT\u2019in geni\u015f \u00e7apl\u0131 tarama planlar\u0131 i\u00e7in cazip ve uygulanabilir bir se\u00e7enek olmaya devam etti\u011fi sonucuna var\u0131l\u0131yor. Ayr\u0131ca, takip prosed\u00fcrlerine hasta kat\u0131l\u0131m\u0131n\u0131n herhangi bir tarama stratejisinin de\u011ferini belirlemede kritik \u00f6neme sahip oldu\u011fu vurgulan\u0131yor.<\/p>\n
\u00c7al\u0131\u015fma, test hassasiyeti ve \u00f6zg\u00fcll\u00fck oranlar\u0131n\u0131n sabit de\u011fil, esnek nitelikte oldu\u011funu ve s\u0131n\u0131r de\u011ferler arac\u0131l\u0131\u011f\u0131yla optimize edilebilece\u011fini de aktar\u0131yor. FIT\u2019nin pozitiflik e\u015fiklerinin ayarlanmas\u0131yla hem tan\u0131sal ba\u015far\u0131 hem maliyet avantaj\u0131 elde edilmesi m\u00fcmk\u00fcn. Bu durum, yeni molek\u00fcler testlerin getirdi\u011fi a\u015f\u0131r\u0131 maliyetlerden ka\u00e7\u0131narak screening sonu\u00e7lar\u0131n\u0131n iyile\u015ftirilmesi i\u00e7in pratik ve umut vaat eden bir yol sunuyor.<\/p>\n
Artan kanser y\u00fck\u00fc ve b\u00fct\u00e7e k\u0131s\u0131tlamalar\u0131n\u0131n ya\u015fand\u0131\u011f\u0131 sa\u011fl\u0131k sistemleri ba\u011flam\u0131nda, bu \u00e7al\u0131\u015fma olduk\u00e7a \u00f6nemli sonu\u00e7lar bar\u0131nd\u0131r\u0131yor. Politika yap\u0131c\u0131lar ve klinisyenlerin ileri tan\u0131 testlerinin getirdi\u011fi k\u00fc\u00e7\u00fck ek faydalar\u0131, sa\u011fl\u0131k sistemlerinin s\u00fcrd\u00fcr\u00fclebilirli\u011fi a\u00e7\u0131s\u0131ndan kritik olan maliyet etkileri ile dengede de\u011ferlendirmesi gerekmekte. Bu denge, tarama programlar\u0131n\u0131n herkes i\u00e7in eri\u015filebilir ve makul fiyatl\u0131 kalmas\u0131na katk\u0131 sa\u011flayacak.<\/p>\n
\u00d6te yandan, FIT\u2019nin kolayl\u0131k ve eri\u015filebilirlik avantajlar\u0131na ra\u011fmen, hi\u00e7bir testin kusursuz olmad\u0131\u011f\u0131 da belirtilmi\u015f. MSDT ve N-G MSDT, genetik ve epigenetik bilgi i\u00e7ermeleri nedeniyle belli hasta gruplar\u0131nda potansiyel ek klinik faydalar sunabilir. Ancak bu faydalar\u0131n, maliyet art\u0131\u015f\u0131 ve etkinlik kar\u015f\u0131la\u015ft\u0131rmalar\u0131 \u0131\u015f\u0131\u011f\u0131nda do\u011frulanmas\u0131 laz\u0131m geliyor. B\u00f6ylelikle, maliyet-etkinlik dengesinin daha hassas \u015fekilde kurulmas\u0131 sa\u011flanabilir.<\/p>\n
Yazarlar, tarama algoritmalar\u0131n\u0131n geli\u015ftirilmesi i\u00e7in risk s\u0131n\u0131fland\u0131rma modellerine entegre edilmi\u015f ki\u015fiye \u00f6zel test se\u00e7imlerinin \u00f6nemine dikkat \u00e7ekiyor. Bu yakla\u015f\u0131m hem FIT hem de multitarget DNA testlerinin g\u00fc\u00e7l\u00fc y\u00f6nlerini bir araya getirerek ki\u015fiye \u00f6zel \u00f6nleme stratejileri sunabilir ve kamu sa\u011fl\u0131\u011f\u0131 b\u00fct\u00e7elerini koruyabilir. Bu t\u00fcr hassas tarama y\u00f6ntemleri ayn\u0131 zamanda gereksiz harcamalar\u0131n \u00f6n\u00fcne ge\u00e7ilmesine olanak tan\u0131r.<\/p>\n
Sonu\u00e7 olarak, bu \u00f6nemli \u00e7al\u0131\u015fma, kolorektal kanser taramas\u0131nda pahal\u0131 multitarget DNA tabanl\u0131 testlere y\u00f6nelik heyecan\u0131 yeniden g\u00f6zden ge\u00e7irmeye \u00e7a\u011f\u0131r\u0131yor. FIT\u2019in maliyet etkinli\u011finin alt\u0131n\u0131 \u00e7izerek daha hesapl\u0131 ve etkili tarama stratejilerinin geli\u015ftirilmesinin gereklili\u011fini vurguluyor. Teknolojik yenilikler ile ekonomik ger\u00e7ek\u00e7ilik aras\u0131nda sa\u011flam bir denge kurmak, kolorektal kanserle m\u00fccadelede kritik bir ad\u0131m olarak \u00f6ne \u00e7\u0131k\u0131yor.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: People Almanya\u2019n\u0131n Heidelberg kentindeki Alman Kanser Ara\u015ft\u0131rma Merkezi taraf\u0131ndan yap\u0131lan \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir \u00e7al\u0131\u015fma, kolorektal kanser (KRK) tarama testlerinde y\u00fcksek hassasiyetin her zaman maliyet etkinli\u011fi art\u0131rmad\u0131\u011f\u0131n\u0131 ortaya koydu. Annals of Internal Medicine dergisinin yakla\u015fan say\u0131s\u0131nda yay\u0131mlanacak ara\u015ft\u0131rmada, geleneksel d\u0131\u015fk\u0131da insan imm\u00fcnokimyasal testi (FIT) ile multitarget d\u0131\u015fk\u0131 DNA testleri (MSDT) ve yeni nesil multitarget d\u0131\u015fk\u0131 DNA testleri…<\/p>\n","protected":false},"author":1,"featured_media":5660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[7488,7486,7485,7487,7484],"tmauthors":[],"class_list":{"0":"post-5659","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-almanya-almanca-kanser-arastirma-merkezi-kolorektal-kanser-calismasi","9":"tag-erken-evre-kolorektal-kanser-tespiti-ekonomik-analiz","10":"tag-fit-ve-msdt-maliyet-etkinligi-karsilastirmasi","11":"tag-kolorektal-kanser-tarama-testlerinde-hasta-uyumu","12":"tag-multitarget-diski-dna-testleri-kolorektal-kanser-taramasi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Multitarget-DNA-Testleri-ve-FIT8217in-Kolorektal-Kanser-Tespiti-1747087161.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5659"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5660"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5659"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nMakale Ba\u015fl\u0131\u011f\u0131<\/strong>: Dollars needed to pay per early-detected colorectal cancer in stool-based screening
\nHaberin Yay\u0131n Tarihi<\/strong>: 13-May-2025
\nWeb References<\/strong>: http:\/\/dx.doi.org\/10.7326\/ANNALS-24-04026
\nDoi Referans<\/strong>: 10.7326\/ANNALS-24-04026
\nAnahtar Kelimeler<\/strong>: Colorectal cancer, Cost effectiveness, Cancer screening, advanced neoplasia detection techniques, colorectal cancer mortality prevention, colorectal cancer screening guidelines, cost-effectiveness of colorectal cancer screening, early detection of colorectal cancer, economic analysis of cancer screening, fecal immunochemical tests comparison, Medicare reimbursement for cancer tests, multitarget stool DNA tests, non-invasive cancer screening methods, patient adherence to colonoscopy follow-ups, sensitivity vs cost in CRC tests<\/p>\n","protected":false},"excerpt":{"rendered":"